Walleye Capital LLC Sells 32,647 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Walleye Capital LLC decreased its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 5.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 536,318 shares of the company’s stock after selling 32,647 shares during the quarter. Walleye Capital LLC owned 0.69% of Kura Oncology worth $4,671,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of KURA. Harbor Advisors LLC purchased a new stake in Kura Oncology during the fourth quarter valued at about $87,000. E Fund Management Co. Ltd. purchased a new stake in Kura Oncology during the 4th quarter valued at about $90,000. Optimize Financial Inc bought a new position in Kura Oncology during the 4th quarter worth approximately $100,000. Corient Private Wealth LLC purchased a new position in Kura Oncology in the 4th quarter worth approximately $109,000. Finally, Teacher Retirement System of Texas lifted its position in Kura Oncology by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock valued at $120,000 after purchasing an additional 2,285 shares during the last quarter.

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,729 shares of company stock valued at $92,307. Corporate insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on KURA. Cantor Fitzgerald raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Scotiabank lowered their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, April 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Price Performance

Shares of KURA stock opened at $5.75 on Thursday. The business’s fifty day moving average is $7.18 and its 200 day moving average is $10.64. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $464.34 million, a price-to-earnings ratio of -2.44 and a beta of 0.83. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $23.48.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analysts’ expectations of $57.96 million. Research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.